responsible for Chagas disease. We selected compound 1 for lead optimization, aiming to improve in parallel its anti-T. cruzi activity (IC50 = 0.63 μM) and its human metabolic stability (human clearance = 9.57 mL/min/g). A total of 39 analogues of 1 were synthesized and tested in vitro. We established a multiparametric structure–activity relationship, allowing optimization of antiparasite activity, physicochemical
酰基
氨基
苯并噻唑命中被确定为克氏锥虫复制的潜在
抑制剂,锥虫是负责恰加斯病的寄生虫。我们选择化合物1进行
铅优化,旨在同时提高其抗克鲁氏锥虫活性(IC 50 = 0.63μM)和其人类代谢稳定性(人类清除率= 9.57 mL / min / g)。总共合成了39种1的类似物,并在体外进行了测试。我们建立了多参数结构与活性的关系,从而可以优化抗寄生虫活性,理化参数和A
DME特性。我们将化合物50鉴定为具有改进的体外抗T. cruzi活性的高级
铅(IC50 = 0.079μM)和增强的代谢稳定性(人类清除率= 0.41 mL / min / g)和口服途径。在耐受性评估后,有50种药物显示出有希望的体内功效。